Vanguard Group
INDP icon

Vanguard Group’s Indaptus Therapeutics INDP Stock Holding History

Vanguard Group’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,152
Closed -$141K – 4304
2025
Q1 		$141K Hold
9,152
– – ﹤0.01% 4102
2024
Q4 		$216K Hold
9,152
– – ﹤0.01% 4095
2024
Q3 		$318K Hold
9,152
– – ﹤0.01% 4067
2024
Q2 		$543K Hold
9,152
– – ﹤0.01% 3979
2024
Q1 		$574K Hold
9,152
– – ﹤0.01% 3981
2023
Q4 		$451K Buy
9,152
+197
+2% +$12.4K ﹤0.01% 4072
2023
Q3 		$691K Buy
8,955
+14
+0.2% +$946 ﹤0.01% 3958
2023
Q2 		$478K Hold
8,941
– – ﹤0.01% 4131
2023
Q1 		$463K Hold
8,941
– – ﹤0.01% 4141
2022
Q4 		$363K Buy
8,941
+4
+0% +$202 ﹤0.01% 4183
2022
Q3 		$541K Buy
8,937
+117
+1% +$9.11K ﹤0.01% 4190
2022
Q2 		$645K Buy
8,820
+169
+2% +$13.2K ﹤0.01% 4219
2022
Q1 		$969K Buy
8,651
+1,365
+19% +$175K ﹤0.01% 4218
2021
Q4 		$1.16M Buy
7,286
+4,577
+169% +$850K ﹤0.01% 4223
2021
Q3 		$594K Buy
+2,709
New +$782K ﹤0.01% 4357

Other funds holding INDP

SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group's INDP Position: Q2 2025 in Review

Vanguard Group sold out of Indaptus Therapeutics (INDP) in Q2 2025, closing a stake of 9,152 shares — an estimated $141K sold.

Vanguard Group first reported a position in INDP in Q3 2021 and held it in 15 quarters. The position peaked at $1.16M in Q4 2021. 5 funds tracked by Wall St. Rank hold INDP as of Q2 2025.

  • Vanguard Group reported no remaining Indaptus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Vanguard Group sold 9,152 Indaptus Therapeutics shares in Q2 2025, an estimated $141K.
  • Vanguard Group first reported a position in Indaptus Therapeutics in Q3 2021 and held it in 15 quarters.
  • Vanguard Group's Indaptus Therapeutics position peaked at $1.16M in Q4 2021.
  • 5 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2025.

Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.